Cargando…
Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitrea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383310/ https://www.ncbi.nlm.nih.gov/pubmed/22740831 http://dx.doi.org/10.1159/000339624 |
_version_ | 1782236607417417728 |
---|---|
author | H.Y. Wu, Zenith Y.Y. Wong, Michelle Y.Y. Lai, Timothy |
author_facet | H.Y. Wu, Zenith Y.Y. Wong, Michelle Y.Y. Lai, Timothy |
author_sort | H.Y. Wu, Zenith |
collection | PubMed |
description | Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitreal ranibizumab. A 57-year-old lady presented with painless loss of vision with a right-eye visual acuity of 20/800. Fundus examination showed a well-demarcated yellowish peripapillary choroidal osteoma with associated retinal and subretinal hemorrhage due to CNV. Three intravitreal ranibizumab injections at monthly intervals were given and her visual acuity improved to 20/30 following treatment. After 1.2 years of follow-up, the right eye visual acuity was maintained at 20/30 with no evidence of CNV recurrence. Our findings suggest that intravitreal ranibizumab may be an effective therapeutic option for treating CNV secondary to choroidal osteoma. |
format | Online Article Text |
id | pubmed-3383310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-33833102012-06-27 Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma H.Y. Wu, Zenith Y.Y. Wong, Michelle Y.Y. Lai, Timothy Case Rep Ophthalmol Published online: June, 2012 Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitreal ranibizumab. A 57-year-old lady presented with painless loss of vision with a right-eye visual acuity of 20/800. Fundus examination showed a well-demarcated yellowish peripapillary choroidal osteoma with associated retinal and subretinal hemorrhage due to CNV. Three intravitreal ranibizumab injections at monthly intervals were given and her visual acuity improved to 20/30 following treatment. After 1.2 years of follow-up, the right eye visual acuity was maintained at 20/30 with no evidence of CNV recurrence. Our findings suggest that intravitreal ranibizumab may be an effective therapeutic option for treating CNV secondary to choroidal osteoma. S. Karger AG 2012-06-12 /pmc/articles/PMC3383310/ /pubmed/22740831 http://dx.doi.org/10.1159/000339624 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: June, 2012 H.Y. Wu, Zenith Y.Y. Wong, Michelle Y.Y. Lai, Timothy Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title | Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title_full | Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title_fullStr | Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title_full_unstemmed | Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title_short | Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma |
title_sort | long-term follow-up of intravitreal ranibizumab for the treatment of choroidal neovascularization due to choroidal osteoma |
topic | Published online: June, 2012 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383310/ https://www.ncbi.nlm.nih.gov/pubmed/22740831 http://dx.doi.org/10.1159/000339624 |
work_keys_str_mv | AT hywuzenith longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma AT yywongmichelle longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma AT yylaitimothy longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma |